HomeCompareCKNHF vs PFE

CKNHF vs PFE: Dividend Comparison 2026

CKNHF yields 2.45% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CKNHF wins by $12.7K in total portfolio value
10 years
CKNHF
CKNHF
● Live price
2.45%
Share price
$60.02
Annual div
$1.47
5Y div CAGR
37.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.2K
Annual income
$14,463.28
Full CKNHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CKNHF vs PFE

📍 CKNHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKNHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKNHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKNHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKNHF
Annual income on $10K today (after 15% tax)
$208.15/yr
After 10yr DRIP, annual income (after tax)
$12,293.79/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $10,026.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKNHF + PFE for your $10,000?

CKNHF: 50%PFE: 50%
100% PFE50/50100% CKNHF
Portfolio after 10yr
$55.9K
Annual income
$20,361.00/yr
Blended yield
36.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CKNHF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.8
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKNHF buys
0
PFE buys
0
No recent congressional trades found for CKNHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKNHFPFE
Forward yield2.45%6.13%
Annual dividend / share$1.47$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37.6%13.2%
Portfolio after 10y$62.2K$49.6K
Annual income after 10y$14,463.28$26,258.71
Total dividends collected$37.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CKNHF vs PFE ($10,000, DRIP)

YearCKNHF PortfolioCKNHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,037$336.95$9,153$693.39+$1.9KCKNHF
2$12,288$478.25$8,593$849.25+$3.7KCKNHF
3$13,833$684.72$8,336$1,066.78+$5.5KCKNHF
4$15,792$991.24$8,437$1,384.80+$7.4KCKNHF
5$18,353$1,455.29$9,013$1,875.40+$9.3KCKNHF
6$21,813$2,174.94$10,306$2,680.72+$11.5KCKNHF
7$26,664$3,324.17$12,820$4,101.38+$13.8KCKNHF
8$33,756$5,225.53$17,673$6,826.70+$16.1KCKNHF
9$44,626$8,507.30$27,543$12,591.86+$17.1KCKNHF
10$62,213$14,463.28$49,560$26,258.71+$12.7KCKNHF

CKNHF vs PFE: Complete Analysis 2026

CKNHFStock

Clarkson PLC provides integrated shipping services worldwide. The company operates through four segments: Broking, Financial, Support, and Research. The Broking segment offers services to ship owners and charterers in the transportation of various cargoes by sea; and to buyers and sellers/yards related to sale and purchase transactions, as well as futures broking operation. This segment deals in containers, deep sea tankers, dry cargo, liquefied petroleum gas and ammonia, liquefied natural gas, offshore, petrochemical gases, renewables, shortsea, specialized products, sale and purchase, and PCTC markets; and towage, salvage, and transportation markets. The Financial segment provides investment banking services for maritime, oil services, and natural resources sectors; structured asset finance services and projects in the shipping, offshore, and real estate sectors; and freight derivative products. This segment also offers equity and fixed income sales and trading; equity and credit research; and corporate access and corporate finance services, including advising clients on various equity and debt capital markets, and M&A transactions. The Support segment provides port and agency, freight forwarding, supplies, and tools for the marine and offshore industries. The Research segment offers shipping-related information and publications; and collects, validates, analyses, and manages data to inform various business decisions. This segment provides web products, such as Shipping Intelligence Network and World Fleet Register to printed publications, including Shipping Intelligence Weekly and Offshore Intelligence Monthly; data and analysis services for IPO and bond issues; customer service contracts, primarily to the financial, government, insurance, equipment, and shipbuilding sectors; and valuations to owners and the financial community. It also offers research and legal services. The company was founded in 1852 and is headquartered in London, the United Kingdom.

Full CKNHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CKNHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKNHF vs SCHDCKNHF vs JEPICKNHF vs OCKNHF vs KOCKNHF vs MAINCKNHF vs JNJCKNHF vs MRKCKNHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.